JP2024501022A5 - - Google Patents

Info

Publication number
JP2024501022A5
JP2024501022A5 JP2023539281A JP2023539281A JP2024501022A5 JP 2024501022 A5 JP2024501022 A5 JP 2024501022A5 JP 2023539281 A JP2023539281 A JP 2023539281A JP 2023539281 A JP2023539281 A JP 2023539281A JP 2024501022 A5 JP2024501022 A5 JP 2024501022A5
Authority
JP
Japan
Prior art keywords
nucleic acid
sequence
acid sequence
talen
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023539281A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501022A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/062749 external-priority patent/WO2022146654A1/en
Publication of JP2024501022A publication Critical patent/JP2024501022A/ja
Publication of JP2024501022A5 publication Critical patent/JP2024501022A5/ja
Pending legal-status Critical Current

Links

JP2023539281A 2020-12-28 2021-12-10 Hbvを標的とする転写活性化因子様エフェクターヌクレアーゼ(talen) Pending JP2024501022A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063131145P 2020-12-28 2020-12-28
US63/131,145 2020-12-28
PCT/US2021/062749 WO2022146654A1 (en) 2020-12-28 2021-12-10 Transcription activator-like effector nucleases (talens) targeting hbv

Publications (2)

Publication Number Publication Date
JP2024501022A JP2024501022A (ja) 2024-01-10
JP2024501022A5 true JP2024501022A5 (enExample) 2024-12-18

Family

ID=80034902

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023539281A Pending JP2024501022A (ja) 2020-12-28 2021-12-10 Hbvを標的とする転写活性化因子様エフェクターヌクレアーゼ(talen)

Country Status (8)

Country Link
US (1) US20240316090A1 (enExample)
EP (1) EP4267740A1 (enExample)
JP (1) JP2024501022A (enExample)
AU (1) AU2021412833A1 (enExample)
CA (1) CA3203442A1 (enExample)
TW (1) TW202242112A (enExample)
UY (1) UY39592A (enExample)
WO (1) WO2022146654A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024211625A1 (en) * 2023-04-07 2024-10-10 Arcturus Therapeutics, Inc. Hbv gene editing
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
CA2285056C (en) 1997-04-03 2004-12-14 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
AU8444798A (en) 1997-06-30 1999-01-25 Centre National De La Recherche Scientifique Improved method for transferring nucleic acid into the striped muscle and combination therefor
US6697669B2 (en) 1998-07-13 2004-02-24 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
CA2532228C (en) 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
HUE025052T2 (en) 2004-03-08 2016-01-28 Ichor Medical Systems Inc A sharpened device for electrically mediated delivery of medical substances
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US8304529B2 (en) 2006-07-28 2012-11-06 Life Technologies Corporation Dinucleotide MRNA cap analogs
CA2666501C (en) 2006-10-17 2017-03-21 Vgx Pharmaceuticals, Inc. Electroporation devices and methods of using same for electroporation of cells in mammals
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
WO2009086558A1 (en) 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
CA2740000C (en) 2008-10-09 2017-12-12 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
CN111808084A (zh) 2008-11-10 2020-10-23 阿布特斯生物制药公司 用于递送治疗剂的新型脂质和组合物
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
SG10201911942UA (en) 2009-05-05 2020-02-27 Muthiah Manoharan Lipid compositions
KR101766408B1 (ko) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
WO2011072246A2 (en) 2009-12-10 2011-06-16 Regents Of The University Of Minnesota Tal effector-mediated dna modification
KR20190039347A (ko) 2010-06-03 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 활성제의 전달을 위한 생분해성 지질
MX342608B (es) 2010-07-06 2016-10-06 Novartis Ag * Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion.
KR101556359B1 (ko) * 2011-01-03 2015-10-01 주식회사 툴젠 디자인된 tal 이펙터 뉴클레아제를 통한 게놈 엔지니어링
MX366055B (es) 2011-08-31 2019-06-26 Novartis Ag Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.
EP2817287B1 (en) 2012-02-24 2018-10-03 Arbutus Biopharma Corporation Trialkyl cationic lipids and methods of use thereof
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
JP6506749B2 (ja) 2013-10-22 2019-04-24 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド フェニルケトン尿症のためのmRNA療法
HUE060907T2 (hu) 2014-06-25 2023-04-28 Acuitas Therapeutics Inc Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
PT3313829T (pt) 2015-06-29 2024-07-08 Acuitas Therapeutics Inc Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
CN120842296A (zh) 2015-09-21 2025-10-28 垂林克生物技术有限公司 用于合成5’-加帽rna的组合物和方法
HRP20230209T1 (hr) 2015-10-28 2023-04-14 Acuitas Therapeutics Inc. Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
WO2017117528A1 (en) 2015-12-30 2017-07-06 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US9834510B2 (en) 2015-12-30 2017-12-05 Arcturus Therapeutics, Inc. Aromatic ionizable cationic lipid
AU2017241925B2 (en) 2016-03-28 2022-01-13 Ichor Medical Systems, Inc. Method and apparatus for delivery of therapeutic agents
US10487105B2 (en) 2016-10-19 2019-11-26 Arcturus Therapeutics, Inc. Trinucleotide MRNA cap analogs
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2018119163A1 (en) 2016-12-21 2018-06-28 Payne Joseph E Ionizable cationic lipid for rna delivery
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
CN110799492B (zh) 2017-04-28 2023-06-27 爱康泰生治疗公司 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
CA3073020A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
WO2019036028A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
EP4501322A3 (en) 2017-08-17 2025-04-16 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations

Similar Documents

Publication Publication Date Title
Wang et al. HBV genome and life cycle
JP2024502210A5 (enExample)
JP6576904B2 (ja) HIV−1プロウイルスDNAのinvivo切除のための組成物及び方法
JP2021178828A (ja) B型肝炎ウイルス感染に対するRNAi療法
CN104107437B (zh) 一种用于治疗乙型病毒性肝炎的rna干扰组合物及其制备方法
CN108136206B (zh) 抗乙型肝炎病毒的组合物和药剂及其用途
JP2021523198A5 (enExample)
CN111372593A (zh) 治疗乙型肝炎感染的方法
JP2024501022A5 (enExample)
JP2025073123A5 (enExample)
Ahmed et al. Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA
KR101954130B1 (ko) B형 간염 예방 또는 치료용 의약 조성물
CN114507663A (zh) 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用
JP2023527875A5 (enExample)
JPWO2018193902A1 (ja) マイクロrnaによるb型肝炎ウイルスに対する抗ウイルス効果
JP2022553375A5 (enExample)
Bassit et al. Moving fast toward hepatitis B virus elimination
Martin Perez et al. Enhancing the therapeutic potential of extracellular vesicles using peptide technology
Alcantara et al. Functional characterization of the interferon regulatory element in the enhancer 1 region of the hepatitis B virus genome
CN113194945B (zh) 环吡酮的抑制hbv核心组装的用途
JP2022529481A (ja) B型肝炎ウイルスの増殖を抑制する組成物及びその方法
KR102273071B1 (ko) B형 간염 예방 또는 치료용 조성물
CN114569743B (zh) 肝特异性的基因编辑纳米药物及其制备方法和应用
Chapus et al. Molecular virology and life cycle of hepatitis B virus
Chen et al. The changing landscape of gene editing tool delivery in neurological disorders